MarketPulse

CDMO

6 articles
GlobeNewswire Inc.GlobeNewswire Inc.··Researchandmarkets.Com

CDMO Formulations Market Surges: 10.6% Growth Forecast Fuels M&A Wave

Pharmaceutical CDMO formulations market projects 10.6% CAGR through 2030, driven by peptide outsourcing and biologic innovations reshaping competitive dynamics.
JBLTMOLZAGYWXXWYmarket growthCDMO
GlobeNewswire Inc.GlobeNewswire Inc.··Sk Pharmteco

SK Pharmteco Convenes Pharma Manufacturing Leaders for Innovation Summit

SK pharmteco hosts April 8 Cambridge symposium on advanced pharmaceutical manufacturing, featuring leaders from Gilead, Eli Lilly, Amgen, and Antheia discussing continuous production innovations.
AMGNLLYGILDCDMOsymposium
GlobeNewswire Inc.GlobeNewswire Inc.··Na

Lifecore Biomedical Lands Third Commercial Site Transfer in Medical Aesthetics Push

Lifecore Biomedical announces third commercial CDMO site transfer since October 2025, targeting 12% revenue CAGR through 2029.
LFCRCDMOcontract manufacturing
BenzingaBenzinga··Vandana Singh

Charles River Labs to Divest CDMO and Discovery Units in Strategic Restructuring

Charles River Labs divests CDMO and discovery units to GI Partners and IQVIA, reducing revenue but boosting profitability and raising 2026 earnings guidance.
CRLIQVearnings guidancedivestiture
GlobeNewswire Inc.GlobeNewswire Inc.··Na

Aquestive Therapeutics to Present at Four Major Healthcare Investor Conferences in March

Aquestive Therapeutics will present at four major healthcare investor conferences in March 2026, updating investors on its clinical pipeline and strategic initiatives.
AQSTinvestor conferencespharmaceutical company
GlobeNewswire Inc.GlobeNewswire Inc.··Na

Aquestive to Disclose Q4 2025 Results and Pipeline Progress on March 4-5

Aquestive Therapeutics will report Q4 2025 results March 4 and hold investor call March 5, discussing financial performance and pipeline progress including Anaphylm™ development.
AQSTclinical dataearnings report